Opioids remain a mainstay for managing moderate-to-severe cancer pain, yet accumulating evidence suggests that opioid analgesics can impair antitumor immunity. In their recent study, McIlvried et al propose a mechanistic framework for how morphine adm…
Asia’s role in cancer immunotherapy research is rapidly expanding, driven by cutting-edge facilities, innovative technologies, and collaborative efforts. This commentary examines the region’s growing impact, highlighting key clinical trial…
Resident Golgi protein 73 (GP73) is expressed in many healthy tissues, however overexpression is associated with both viral infections and cancer. As an oncoprotein, GP73 drives tumor progression and plays a fundamental role in immune regulation. A re…
Understanding regional distribution of HLA frequencies is crucial for optimizing enrollment in HLA-restricted clinical trials and to promote trial diversity per the Food and Drug Administration’s 2020 mandate. Using US HLA frequency data and cen…
Background
Endogenous retroviruses (ERVs) are remnants of retrovirus germline infections that occurred over the course of evolution and constitute between 5% and 8% of the human genome. While ERVs tend to be epigenetically silenced in normal adult hum…
Background
Dupilumab has been added to National Cancer Comprehensive Network guidelines as a therapeutic strategy for managing certain cutaneous immune-related adverse events (cirAEs) from immune checkpoint blockade (ICB). However, little is known abo…
Background
Immune checkpoint inhibitors (ICIs) have led to enduring responses in subsets of patients with cancer. However, these responses carry the risk of immune-related adverse events (irAEs), which can diminish the overall benefit of ICI treatment…
Background
Pancreatic cancer has a complex immunosuppressive tumor microenvironment (TME), which is highly resistant to conventional therapies and emerging cancer immunotherapies. Oncolytic viruses are multifaceted killers of malignant tumors, which c…
